In clarification

Pharmacoepidemiology and Drug Safety

Volumn 16, Issue 10, 2007, Pages 1063-1064

  Strom, Brian L ^a   Lewis, James D ^a   McAfee, Andrew T ^b   Walker, Alexander M ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b i3 Drug Safety   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE;

COHORT ANALYSIS; DRUG INDUSTRY; DRUG RESEARCH; DRUG SAFETY; DRUG USE; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HEART INFARCTION; HUMAN; METHODOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK ASSESSMENT; SAMPLE SIZE; SCORING SYSTEM; UNITED STATES;

HUMANS; HYPOGLYCEMIC AGENTS; MYOCARDIAL INFARCTION; THIAZOLIDINEDIONES;

EID: 35648952249     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1474     Document Type: Editorial

References (3)

1. Gerrits C, Bhattacharya M, Manthena S, Baran R, Perez A, Kupfer K. A comparison of Pioglitazone and Rosiglitazone for hospitalization for myocardial infarction in type 2 diabetes. Pharmacoepidemiol Drug Saf DOI: 10.1002/pds 1470.
2. McAfee AT, Koro C, Landon J, Ziyadeh N, Walker AM. Coronary heart disease outcomes in patients receiving antidiabetic agents. Pharmacoepidemiol Drug Saf 2007; 16: 711-725.
3. Johannes CB, Koro CE, Quinn SG, Cutone JA, Seeger JD. The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy. Pharmacoepidemiol Drug Saf 2007; 16: 504-512.